`sclerosis drug [Novantrone] in
`U.S.
`
`Created 11/13/2002 - 12:30
`By Kim Frick and Chantal Pfenniger
`SOURCE: [Bloomberg [1]]
`Geneva, Nov. 13 (Bloomberg) -- Serono SA, Europe's biggest
`biotechnology company, agreed to sell Amgen Inc.'s multiple sclerosis
`medicine Novantrone in the U.S.
`The companies didn't disclose the terms of the agreement. Novantrone
`last year generated U.S. sales of $71 million after regulators approved the
`drug for multiple sclerosis in October 2000. Amgen obtained the drug
`when it acquired Immunex Corp. in July 2002.
`Serono is trying to expand in the $2.5 billion worldwide market for multiple
`sclerosis treatments. The Geneva-based company already sells the
`medicine Rebif, which accounted for 40 percent of sales in the third
`quarter.
`"It's a good move and shows Serono is really interested in building their
`MS franchise,'' said Dorothea Koeppe, an analyst at Lombard Odier
`Darier Hentsch & Cie., who recommends buying shares of Serono.
`Serono shares rose 5 Swiss francs, or 0.6 percent to 830 francs, as of
`12:09 p.m. in Zurich trading. The shares have declined 43 percent this
`year.
`
`5/27/2015
`
`Serono to sell Amgen multiple sclerosis drug [Novantrone] in U.S. - FirstWord Pharma Print
`
`http://www.firstwordpharma.com/print/212958?tsid=17
`
`1/2
`
`MYLAN PHARMS. INC. EXHIBIT 1117 PAGE 1
`
`
`
`Cancer Drug
`Novantrone treats patients with the less common "secondary progressive''
`form of the disease and is generally reserved for patients who no longer
`respond to other drugs. Side effects including low white-blood-cell counts
`and heart problems are associated with the medicine.
`The drug is also used to treat acute non-lymphocytic leukemia, and
`because of its toxicity the U.S. Food and Drug Administration
`recommends patents not ordinarily receive more than eight to 12 doses
`over two or three years.
`"It will give Serono access to new patients, but it's only a small part of new
`patients,'' Koeppe said.
`Serono is also working with U.S. drugmaker Ivax Corp. to develop a
`multiple sclerosis treatment, which may be the world's first effective oral
`medicine for the disease. Current drugs for MS must be injected.
`Multiple sclerosis is a disabling neurological disease that interferes with
`messages sent between the brain and other parts of the body. Patients
`can experience loss of limb control, fatigue and partial blindness.
`Earlier this year, Serono won U.S. approval to sell Rebif for relapsing
`forms of the disease. Symptoms in relapsing-remitting patients may ease
`or disappear for months while patients with secondary progressive forms
`of the disease have more severe symptoms.
`Copyright, Bloomberg L.P.
`
`FirstWord Pharma is a reliable news service providing an efficient and
`timely global overview of the news and events impacting the
`pharmaceutical industry.
`To access additional articles of interest, please visit
`www.firstwordpharma.com.
`
`© 2015 Doctor's Guide Publishing Limited. All Rights Reserved.
`
`5/27/2015
`
`Serono to sell Amgen multiple sclerosis drug [Novantrone] in U.S. - FirstWord Pharma Print
`
`http://www.firstwordpharma.com/print/212958?tsid=17
`
`2/2
`
`MYLAN PHARMS. INC. EXHIBIT 1117 PAGE 2
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
